Mechanisms of disease:: the role of aldosterone in kidney damage and clinical benefits of its blockade

被引:50
作者
Del Vecchio, Lucia
Procaccio, Mirella
Vigano, Sara
Cusi, Daniele
机构
[1] IRCCS MultiMed, Hypertens & Prevent Nephrol Unit, I-20099 Milan, Italy
[2] Univ Milan, Grad Sch Nephrol, I-20122 Milan, Italy
来源
NATURE CLINICAL PRACTICE NEPHROLOGY | 2007年 / 3卷 / 01期
关键词
aldosterone; chronic kidney disease; eplerenone; proteinuria; spironolactone;
D O I
10.1038/ncpneph0362
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In the past 10 years, many widely accepted concepts related to aldosterone production and its pathogenetic role have changed. We now know that aldosterone is produced not only by the zona glomerulosa of the adrenal cortex, but also in the heart, blood vessels, kidney and brain; such extra-epithelial production occurs mainly during tissue repair. Also, increased aldosterone levels contribute to vessel inflammation, oxidative stress, endothelial dysfunction and organ damage. As such, aldosterone has a key role in the development of myocardial fibrosis. Anti-aldosterone treatment has proven effective in patients with heart failure. Experimental evidence regarding the role of aldosterone in kidney damage has accumulated. Aldosterone infusion can counteract the beneficial effects of treatment with angiotensin-converting-enzyme inhibitors, causing more-severe proteinuria and an increased number of vascular and glomerular lesions; treatment with aldosterone antagonists can reverse these alterations. Preliminary observations in pilot studies in humans confirm the experimental findings, supporting the hypothesis that aldosterone antagonists are renoprotective in clinical practice. Studies in larger populations with longer follow-up are needed to confirm this theory.
引用
收藏
页码:42 / 49
页数:8
相关论文
共 57 条
[1]   Do human vascular endothelial cells produce aldosterone? [J].
Ahmad, N ;
Romero, DG ;
Gomez-Sanchez, EP ;
Gomez-Sanchez, CE .
ENDOCRINOLOGY, 2004, 145 (08) :3626-3629
[2]   Regression of existing glomerulosclerosis by inhibition of aldosterone [J].
Aldigier, JC ;
Kanjanbuch, T ;
Ma, LJ ;
Brown, NJ ;
Fogo, AB .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (11) :3306-3314
[3]   Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole [J].
Arima, S ;
Kohagura, K ;
Xu, HL ;
Sugawara, A ;
Uruno, A ;
Satoh, F ;
Takeuchi, K ;
Ito, S .
HYPERTENSION, 2004, 43 (02) :352-357
[4]   Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study [J].
Bianchi, S ;
Bigazzi, R ;
Campese, VM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (01) :45-51
[5]   Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats [J].
Blasi, ER ;
Rocha, R ;
Rudolph, AE ;
Blomme, EAG ;
Polly, ML ;
McMahon, EG .
KIDNEY INTERNATIONAL, 2003, 63 (05) :1791-1800
[6]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[7]  
BRILLA CG, 1992, J LAB CLIN MED, V120, P893
[8]   Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo [J].
Brown, NJ ;
Nakamura, S ;
Ma, LJ ;
Nakamura, I ;
Donnert, E ;
Freeman, M ;
Vaughan, DE ;
Fogo, AB .
KIDNEY INTERNATIONAL, 2000, 58 (03) :1219-1227
[9]   Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. [J].
Chrysostomou, A ;
Becker, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :925-926
[10]   CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES [J].
CONN, JW ;
KNOPF, RF ;
NESBIT, RM .
AMERICAN JOURNAL OF SURGERY, 1964, 107 (01) :159-172